Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.37 |
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 11/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602609 | 0.76 | PDE3B (0.32) | RENPDE3BPDE3A | |
| SCHEMBL5802317 | 0.76 | L3MBTL1 (0.43) | DUTBRD4 | |
| SCHEMBL9826702 | 0.73 | F2 (0.47) | — | |
| SCHEMBL3602611 | 0.73 | — | — | |
| SCHEMBL20786215 | 0.71 | PTGDR (0.33) | RENDUT | |
| SCHEMBL3592107 | 0.70 | REN (0.46) | RENBRD4 | |
| SCHEMBL10129667 | 0.70 | PDE3B (0.50) | RENPDE3BPDE3A | |
| SCHEMBL10129678 | 0.70 | PDE3B (0.50) | RENPDE3BPDE3A | |
| SCHEMBL31444786 | 0.67 | F2 (0.44) | PPARGBRD4 | |
| SCHEMBL15337508 | 0.67 | DUT (0.34) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | REN 373/4885DUT 4353/4885PPARG 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.